BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zbinden D, Manuel O. Influenza vaccination in immunocompromised patients: efficacy and safety. Immunotherapy 2014;6:131-9. [DOI: 10.2217/imt.13.171] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Buchy P, Badur S. Who and when to vaccinate against influenza. International Journal of Infectious Diseases 2020;93:375-87. [DOI: 10.1016/j.ijid.2020.02.040] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
2 Trebbien R, Christiansen CB, Fischer TK. Antiviral resistance due to deletion in the neuraminidase gene and defective interfering-like viral polymerase basic 2 RNA of influenza A virus subtype H3N2. J Clin Virol 2018;102:1-6. [PMID: 29448067 DOI: 10.1016/j.jcv.2018.02.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
3 Trebbien R, Pedersen SS, Vorborg K, Franck KT, Fischer TK. Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014. Euro Surveill 2017;22:30445. [PMID: 28128091 DOI: 10.2807/1560-7917.ES.2017.22.3.30445] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 6.6] [Reference Citation Analysis]
4 Lee ARYB, Wong SY, Chai LYA, Lee SC, Lee MX, Muthiah MD, Tay SH, Teo CB, Tan BKJ, Chan YH, Sundar R, Soon YY. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis. BMJ 2022;376:e068632. [PMID: 35236664 DOI: 10.1136/bmj-2021-068632] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 24.0] [Reference Citation Analysis]
5 Hebert KD, Mclaughlin N, Galeas-Pena M, Zhang Z, Eddens T, Govero A, Pilewski JM, Kolls JK, Pociask DA. Targeting the IL-22/IL-22BP axis enhances tight junctions and reduces inflammation during influenza infection. Mucosal Immunol 2020;13:64-74. [PMID: 31597930 DOI: 10.1038/s41385-019-0206-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
6 Hodinka RL. Respiratory RNA Viruses. Microbiol Spectr 2016;4. [PMID: 27726802 DOI: 10.1128/microbiolspec.DMIH2-0028-2016] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 3.4] [Reference Citation Analysis]
7 Rensink MJ, van Laarhoven HWM, Holleman F. Cocoon vaccination for influenza in patients with a solid tumor: a retrospective study. Support Care Cancer 2021;29:3657-66. [PMID: 33179137 DOI: 10.1007/s00520-020-05883-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Lopez A, Mariette X, Bachelez H, Belot A, Bonnotte B, Hachulla E, Lahfa M, Lortholary O, Loulergue P, Paul S. Vaccination recommendations for the adult immunosuppressed patient: A systematic review and comprehensive field synopsis. J Autoimmun. 2017;80:10-27. [PMID: 28381345 DOI: 10.1016/j.jaut.2017.03.011] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 13.8] [Reference Citation Analysis]
9 Dos Santos G, Haguinet F, Cohet C, Webb D, Logie J, Ferreira GL, Rosillon D, Shinde V. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: A self-controlled case-series. Vaccine 2016;34:3598-606. [DOI: 10.1016/j.vaccine.2016.05.016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
10 Tso GHW, Reales-Calderon JA, Pavelka N. The Elusive Anti-Candida Vaccine: Lessons From the Past and Opportunities for the Future. Front Immunol 2018;9:897. [PMID: 29755472 DOI: 10.3389/fimmu.2018.00897] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
11 Cohet C, Haguinet F, Dos Santos G, Webb D, Logie J, Lc Ferreira G, Rosillon D, Shinde V. Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series. BMJ Open 2016;6:e009264. [PMID: 26823177 DOI: 10.1136/bmjopen-2015-009264] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
12 Eibl MM, Wolf HM. Vaccination in patients with primary immune deficiency, secondary immune deficiency and autoimmunity with immune regulatory abnormalities. Immunotherapy 2015;7:1273-92. [PMID: 26289364 DOI: 10.2217/IMT.15.74] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 5.1] [Reference Citation Analysis]
13 Sun P, Kim Y, Lee H, Kim J, Han BK, Go E, Kwon S, Kang JG, You S, Kwon J. Carrot Pomace Polysaccharide (CPP) Improves Influenza Vaccine Efficacy in Immunosuppressed Mice via Dendritic Cell Activation. Nutrients 2020;12:E2740. [PMID: 32916825 DOI: 10.3390/nu12092740] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Gutierrez AF, Sahly HE. Recombinant hemagglutinin protein vaccine: a new option in immunization against influenza. Future Virology 2015;10:1057-67. [DOI: 10.2217/fvl.15.75] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
15 Henn W. Allocation criteria for an initial shortage of a future SARS-CoV-2 vaccine and necessary measures for global immunity. Vaccine 2020;38:5396-7. [PMID: 32600909 DOI: 10.1016/j.vaccine.2020.06.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
16 Samson SI, Leventhal PS, Salamand C, Meng Y, Seet BT, Landolfi V, Greenberg D, Hollingsworth R. Immunogenicity of high-dose trivalent inactivated influenza vaccine: a systematic review and meta-analysis. Expert Review of Vaccines 2019;18:295-308. [DOI: 10.1080/14760584.2019.1575734] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
17 Doneddu PE, Spina E, Briani C, Fabrizi GM, Manganelli F, Nobile-Orazio E; Italian Peripheral Nervous System Association (ASNP). Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP). J Peripher Nerv Syst 2021;26:148-54. [PMID: 33620123 DOI: 10.1111/jns.12435] [Reference Citation Analysis]
18 Singla M, Grossman A, Shikha D, Baumstein D, Chaudhari A, Carbajal R. Influenza and End-Stage Renal Disease: A Fatal Combination. Am J Ther 2016;23:e1096-8. [PMID: 25415542 DOI: 10.1097/MJT.0000000000000136] [Reference Citation Analysis]
19 Jethwa H, Sullivan A, Abraham S. COVID-19 and Immunomodulatory Therapy - Can We Use Data from Previous Viral Pandemics? J Rheumatol 2020;47:1734-7. [PMID: 32423974 DOI: 10.3899/jrheum.200527] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Ngoh HL, Ng MC. Vaccination in the primary care setting: when is it safe to proceed? Singapore Med J 2016;57:3-7. [PMID: 26831309 DOI: 10.11622/smedj.2016004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Robertson CA, DiazGranados CA, Decker MD, Chit A, Mercer M, Greenberg DP. Fluzone® High-Dose Influenza Vaccine. Expert Rev Vaccines 2016;15:1495-505. [PMID: 27813430 DOI: 10.1080/14760584.2016.1254044] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]